Use of transporter knockdown caco-2 cells to investigate the in vitro efflux of statin drugs

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1196-1202

  Li, Jibin ^a   Volpe, Donna A ^b   Wang, Ying ^a   Zhang, Wei ^a   Bode, Chris ^a   Owen, Albert ^a   Hidalgo, Ismael J ^a  

^a Absorption Systems   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; FLUINDOSTATIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 2; ROSUVASTATIN; SHORT HAIRPIN RNA;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

BLOTTING, WESTERN; CACO-2 CELLS; CARRIER PROTEINS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 79959434557     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038075     Document Type: Article

References (33)

1. Asberg A, Hartmann A, Fjeldså E, Bergan S, and Holdaas H (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382-386. (Pubitemid 33681704)
2. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, and Whitfield L (2000) Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40:91-98.
3. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, and Smolarek TA (2005a) Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537-546. (Pubitemid 40393197)
4. Chen C, Slitt AL, Dieter MZ, Tanaka Y, Scheffer GL, and Klaassen CD (2005b) Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. Biochem Pharmacol 70:1088-1095. (Pubitemid 41262084)
5. Chen C, Lin J, Smolarek T, and Tremaine L (2007) P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 35:1725-1729. (Pubitemid 47481596)
6. Echeverri CJ and Perrimon N (2006) High-throughput RNAi screening in cultured cells: a user's guide. Nat Rev Genet 7:373-384.
7. Elsby R, Surry DD, Smith VN, and Gray AJ (2008) Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140-1164.
8. Garnett WR, Venitz J, Wilkens RC, and Dimenna G (1994) Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 96:84S-86S.
9. Hidalgo IJ (2001) Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 1:385-401.
10. Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, and Prueksaritanont T (2004) Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1686-1691. (Pubitemid 41184401)
11. Holtzman CW, Wiggins BS, and Spinler SA (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26:1601-1607. (Pubitemid 44704473)
12. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
13. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
14. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, and Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637. (Pubitemid 36638089)
15. Kantola T, Kivistö KT, and Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65. (Pubitemid 28377331)
16. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, and Niemi M (2008) ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84:457-461.
17. Keskitalo JE, Pasanen MK, Neuvonen PJ, and Niemi M (2009a) Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617-1624.
18. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, and Niemi M (2009b) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
19. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
20. Kittler R, Heninger AK, Franke K, Habermann B, and Buchholz F (2005) Production of endoribonuclease-prepared short interfering RNAs for gene silencing in mammalian cells. Nat Methods 2:779-784. (Pubitemid 41486210)
21. Lindahl A, Sjöberg A, Bredberg U, Toreson H, Ungell AL, and Lennernäs H (2004) Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol Pharm 1:347-356.
22. Martin PD, Kemp J, Dane AL, Warwick MJ, and Schneck DW (2002) No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 42:1352-1357. (Pubitemid 35373605)
23. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, and Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68:391-400.
24. Montgomery MK and Fire A (1998) Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet 14:255-258. (Pubitemid 28341782)
25. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581. (Pubitemid 44908269)
26. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
27. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
28. Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, Barrionuevo LS, Lichter P, and Mertens D (2008) Off-target effects of siRNA specific for GFP. BMC Mol Biol 9:60.
29. Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, and Hidalgo IJ (2008) Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm 356:12-18.
30. Watanabe T, Onuki R, Yamashita S, Taira K, and Sugiyama Y (2005) Construction of a functional transporter analysis system using MDR1 knockdown Caco-2 cells. Pharm Res 22:1287-1293. (Pubitemid 41176032)
31. Wu X, Whitfield LR, and Stewart BH (2000) Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 17:209-215. (Pubitemid 30158371)
32. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, et al. (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103. (Pubitemid 44292182)
33. Zhang W, Li J, Allen SM, Weiskircher EA, Huang Y, George RA, Fong RG, Owen A, and Hidalgo IJ (2009) Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA. Drug Metab Dispos 37:737-744.